Tetracycline-Derivatives for Treatment of Cerebral Arteriovenous Malformations and Aneurysms

Study Overview
=================
Brief Summary
-----------------
The purpose of this pilot study is to investigate the use of minocycline and doxycycline as medical therapy for inoperable or partially treated arteriovenous malformations (AVMs) and giant aneurysms.

Detailed Description
-----------------
Arteriovenous malformations (AVMs) are a treatable cause of stroke in young adults. The processes by which AVMs and giant aneurysms grow in size and spontaneously bleed are unknown. The primary reason to treat AVMs and aneurysms is to guard against intracranial bleeding. This pilot study will examine the use of two common antibiotics-minocycline and doxycycline-as medical therapy for inoperable or partially treated AVMs and giant aneurysms. These drugs, which are tetracycline derivatives, can reduce the levels of a family of enzymes, called matrix metalloproteases, that degrade tissue and thereby cause a reduction in the risk of spontaneous bleeding from AVMs or aneurysm-which is the main cause of stroke associated with these disorders. The enzymes can contribute to weaknesses in the wall of blood vessels and may increase the risk of the vessel wall rupturing and causing spontaneous bleeding. This trial also will show that taking minocycline and doxycycline over an extended period in this patient population is safe and well tolerated. Results from this study could help plan future studies to benefit patients with abnormal blood vessels prone to bleeding in their brains.

Official Title
-----------------
Tetracycline-Derivatives for Treatment of Cerebral Arteriovenous Malformations and Aneurysms

Conditions
-----------------
Aneurysms, Arteriovenous Malformations

Intervention / Treatment
-----------------
* Drug: minocycline
* Drug: doxycycline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Giant aneurysms or brain arteriovenous malformations (BAVM) Female patients of child bearing age using effective birth control, males Creatinine no greater than 2.0 mg/dl ALT no greater than 2 times upper limit of control Exclusion Criteria: Unstable medical illness Contraindications to Tetracycline History of vestibular disease, (except benign positional vertigo) Prior tetracycline use within 2 mos of baseline visit. History of noncompliance with treatment or other protocols History of systemic lupus Patients not eligible for MRI

Ages Eligible for Study
-----------------
Minimum Age: 13 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Brain AVMs<br>This trial is to investigate the use of minocycline or doxycycline as medical therapy, can minocycline or doxycycline induce biologically significant changes in the enzyme system thought to be related to spontaneous growth/rupture of these malformations. Finally, can patients safely tolerate these medications over an extended period of time. | Drug: minocycline<br>* Take minocycline 50mg BID x2 years. Labs drawn at baseline, then every-6 months. MRI is done at baseline and completion of study.<br>Drug: doxycycline<br>* Take doxycycline 50mg BID x2 years. Labs drawn at baseline, then every-6 months. MRI is done at baseline and completion of study.<br>|
| Active Comparator: Aneurysms<br> | Drug: minocycline<br>* Take minocycline 50mg BID x2 years. Labs drawn at baseline, then every-6 months. MRI is done at baseline and completion of study.<br>Drug: doxycycline<br>* Take doxycycline 50mg BID x2 years. Labs drawn at baseline, then every-6 months. MRI is done at baseline and completion of study.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MRI will be done baseline and post treatment. |  | 2 years | 
| MMP levels are being followed q 6-mos. |  | Patients called weekly for 1st-3 months, then every 6-months until completion of study | 
| Drug levels are being followed q 6-mos. |  | Patients called weekly for 1st-3 months, then every 6-months until completion of study | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
minocycline, giant aneurysms, arteriovenous malformations, doxycycline, BAVM